How does it compare to Merck's Emend (aprepitant), which is also an NK-1? Get familiar with the results of an ASCO 2008 abstract titled, "Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)." That's quite a title.
- Treatment for Nausea/Vomiting -- Chemotherapy Induced
- Nausea/Vomiting -- Postoperative
The conclusion is simple: A single oral dose of casopitant added to a regimen of OND/DEX provided a clinically significant reduction in the number of pts experiencing CINV events over the first 5 days after HEC. This benefit appeared to be maintained through repeat cycles. This regimen was generally well tolerated over all cycles.
Well, it's far to early to say which of these drugs will be better and GSK is facing major regulatory hurdles and delays with the FDA:ReplyDelete